Haythem Ali

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, Martin Schlumberger, Stefan Müller et al. · Journal of Clinical Oncology · 2013 · 1.2K citations · Full text

Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process

Cathy Bennett, Nimish Vakil, Jacques Bergman et al. · Gastroenterology · 2012 · 376 citations · Full text

Surgical Oncology, Esophagus, Esophageal Cancer +11

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Martin Schlumberger, Rossella Elisei, Stefan Müller et al. · Annals of Oncology · 2017 · 226 citations · Full text

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Denise A. Yardley, Rob Coleman, Pierfranco Conté et al. · Annals of Oncology · 2018 · 130 citations · Full text